The Michael J. Fox Foundation has awarded three new grants totaling $5.2 million to Arizona State University to explore three pioneering treatments for Parkinson’s disease. The grants will be used to explore 3 pioneering treatments.
The awards will fund research led by Principal Investigator Jeffrey Kordower, each targeting underlying causesof the disease, which currently affects nearly 1 million people in the U.S. alone.
The new projects focus on two primary hallmarks of Parkinson’s disease: the loss of dopamine-producing neurons in the brain and the accumulation within nerve cells of a misfolded form of the protein alpha-synuclein (α-syn).
Kordower is the founding director of the ASU-Banner Neurodegenerative Disease Research Center at Arizona State University and the Charlene and J. Orin Distinguished Director at the Biodesign Institute.
Parkinson’s disease is a leading neurodegenerative ailment, whose symptoms include rigidity, tremors and difficulty with balance and walking. In many cases, problems with movement are accompanied by serious cognitive impairment, including dementia.
Currently, the number of patients living with Parkinson’s disease exceeds those living with multiple sclerosis, muscular dystrophy and ALS (Lou Gehrig’s disease) combined. By 2040, the disease is expected to affect 14 million individuals worldwide.
Parkinson’s disease is a highly diverse disorder, affecting individuals in different ways. While some treatments exist for the constellation of movement disorders common in Parkinson’s patients, the most crippling aspect — severe cognitive impairment — remains untreatable at present.
“Professor Kordower’s approaches to the treatment of this devastating affliction qualify as truly revolutionary,” said Joshua LaBaer, executive director of the Biodesign Institute at ASU. “The brain is our most critical organ, essential to all bodily function as well as the repository of our selfhood. Replacing disease-damaged cells and selectively targeting disease-linked protein accumulations are techniques rapidly moving from the realm of science fiction to science fact.”
Kordower has been on the forefront of research into so-called neural grafting, in which stem cells are directly implanted in the brain. Earlier research by Kordower and others has demonstrated that under proper conditions, implanted cells can develop into the appropriate form of functional neuron, spread their nervous tentacles through damaged tissue, reconnect circuitry disabled by disease and restore function.
The first study will involve a human clinical trial, in collaboration with several centers, including the Barrow Neurological Institute in Phoenix. The approach involves infusing specially designed stem cells into the striatum where dopamine is lost. This project will be conducted in collaboration with Patrik Brundin with the Van Andel Institute, Michigan, and Virginia Mattis with Fuji-CDI, Wisconsin.
Unlike neurons and other highly specialized cell types, stem cells have the remarkable ability to develop into any cell type in the body, under proper conditions. The stem cells used for the brain implants begin their lives as blood cells. A laboratory treatment process causes these cells to undergo de-differentiation into stem cells known as induced pluripotent cells.
Research has shown that implanted cells of this type can recognize their location in the brain, develop into the proper cell type — in this case, nigral neurons — and begin dispensing dopamine, just as their naturally-occurring counterparts did before they were destroyed.
Dr. Paul Larson from the University of Arizona will perform the neurosurgeries at Barrow Neurological Institute, which will ease the patients’ burden by having them receive their surgery and imaging procedures at the same institution; a unique organization made possible by the colleagueship and generosity of Dr. Michael Lawton, CEO of Barrow Neurological Institute.
Patients who receive one or two doses of cells will be evaluated using PET scans and will be periodically re-examined to identify any adverse effects of the procedure and to assess the effectiveness of the therapy in treating symptoms of the disease. This method may not be effective in all cases of Parkinson’s, especially those who received the treatment too late because their brains were too severely damaged by the disease to recover. Because of the complexity of Parkinson’s disease, other factors may be undermining the dopamine system, and teasing out the results is challenging.
The current study aims to clarify and fine-tune the implantation approach by selecting patients with perceptible deficit due to Parkinson’s disease but not so severe that the damage is irreparable. Secondly, the study will attempt to simplify the picture by focusing on a select subset of Parkinson’s patients, namely those with a specific mutation known as a Parkin mutation.
Parkin is a genetic mutation that causes the motor deficits seen in spontaneously occurring, or idiopathic, Parkinson’s disease. Unlike these patients, however, those with Parkin mutations typically display only the classic Parkinsonian symptoms because their disease is pathologically limited to degeneration of the dopamine system. This makes them ideal subjects for a clinical trial to restore dopaminergic cells in the striatum.
“We can transplant stem cells that are, by all accounts, like the nigral neurons that die in Parkinson’s disease,” Kordower said. “They have the same chemical properties; they have the same genetic material that tells them where to go.”
Patients receiving the new cells are expected to show improvements in symptoms in six to 12 months. Successful results in the clinical trial of Parkin mutation cases will thereby encourage further trials in a wider population of Parkinson’s patients.
The second study takes on an even more radical approach to addressing dopamine deficit. This recently discovered technique also aims to produce dopaminergic neurons to replace those depleted in the substantia nigra, but instead of inducing laboratory stem cells to become neurons and then implanting them, the technique converts supportive cells in the brain known as astrocytes into dopaminergic neurons.
Although neurons in the brain often grab most of the attention in the neuroscience community, astrocytes are an underappreciated cell type with many important functions in the central nervous system. They help maintain the blood-brain barrier, modulate neuroinflammation and release factors that stimulate the growth of nervous tissue.
Astrocytes are attractive cell candidates for reprogramming as they lie in the neural vicinity of neurons and are liberally distributed throughout the brains of all mammals. Indeed, the astrocyte population accounts for about half of the total cells in the brain.
Researchers have found that treating astrocytes to deplete a specific RNA-binding protein known as PTB can induce these cells to transition into new neurons capable of repopulating neural circuits damaged by disease. The current study will advance the quest to successfully convert midbrain astrocytes to dopaminergic neurons, reconstitute injured nigrostriatal circuits, restore proper dopamine levels and prevent or reverse the characteristic symptoms of Parkinson’s disease in a pre-clinical animal model of Parkinson’s. These experiments will be guided by Fluorodopa PET scan imaging, which will be done in collaboration with the Barrow Neurological Institute.
The last of the three projects, in collaboration with ASU-Banner co-principal investigators Anne Messer and David Butler, of the New York Stem Cell Institute, targets α-syn accumulation in the brain, using a gene therapy technique. Here, a kind of engineered antibody known as a nanobody will be introduced to reduce α-syn.
One goal of the pre-clinical study is to demonstrate that nanobodies can successfully transduce cells throughout the brain, target accumulations of α-syn, bind with them and shuttle them to a cell structure known as the proteosome, where they are destroyed, much like a corrupted file being dragged to the garbage icon on a computer desktop.
Researchers are hopeful that global expression of the nanobodies following their injection in the cisterna, a region near the brainstem, will result in decreased α-syn load in specific areas of the cerebral cortex associated with cognitive decline in Parkinson’s disease.
Biodistribution and proper functioning of nanobodies will be further explored using a human brain organoid system in the laboratory. Should the technique prove successful, researchers plan to pursue FDA approval for its use in clinical trials under Investigative New Drug status.
Information originally provided by Arizona State University.